biostudies-literatureUnknown9(2)Tanaka AAstellas Pharma US<h4>Aims</h4>To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients.<h4>Methods and results</h4>In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator-initiated clinical trial, adults with type 2 diabetes and haemoglobin A1C (HbA1c) of 6.0-10.0% (42-86 mmol/mol) were randomized equally to ipragliflozin (50 mg daily) and non-sodium-glucose cotransporter-2 (SGLT2) inhibitor use of standard-care (control group) for type 2 diabetes and were followed-up to 24 months. The primary endpoint was the change in mean common carotid artery IMT (CCA-IMT) from baseline to 24 months. A total of 482 patients were equally allocated to the ipragliflozin (N = 241) and control (N = 241) groups, aEuropean heart journal. Cardiovascular pharmacotherapy165-172https://www.ebi.ac.uk/biostudies/studies/S-EPMC9892869biostudies-literatureEffect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.PMC9892869Kajikawa MHisauchi IYoshiyama MKanbara TMiura SINasuno TOgata YTakahara KOhguchi SKitakaze MMurohara TSugimoto KOtsuka TFukae STeragawa HInoue TEguchi KKuroda AKurano MYamashina AKanda JYamada HMaruhashi TTakamori AShiga YKoikawa KPROTECT study investigatorsMachii NFuruta MArimura TDoi MIshihara MKishi HKoyosue AIkehara YNarisawa MAsano HShuto TAjioka MHigashi YTakase BKitagawa KKoga SUchimura YHironori KShibata YTanaka KUehara HSakuma MSohmiya KMirii JWakami KFukumoto KYoshida ROhte NNanasato MYoshida HBando YNakano JKaneko TKanzaki YIzumi KKondo TNishio KKageyama MFukuda DYoshida YNishio YMiyagi NShimabukuro MHirose MMorimoto RKubota YAko JOshita CHoshiga MKoide YUmikawa MYasuda KKusunose KChiba SToyoda SHoshide SKishimoto SAso YMaeda MOkumura TTakenaka MNakamura KKawano HTeruo JNakamura INode KIkeda STanaka AOsanai HToshie ISakamoto YTakemoto YAbe MNakashima YKodama KSugiura TKadokami TNakamura ROrita YSakamoto TTaguchi ISuzuki STokutsu ASuzuki MKawabata YKuriyama NKurozumi AHayashi TKomori TSuzuki HMaemura KMori MOgura YUemura FOguri MMinami HSugihara MYagi SYamaguchi KIshizu TAndo SJinnouchi HKabutoya TMatsunaga KOhishi MChinen TSata MAsaka MUeda SMatsuhisa MTomiyama HGima YKudo AOkada YIse TKamiya HHatano SSonoda SShimizu WKario KAkasaki YMiyazaki MNago CfalseEffect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.<h4>Aims</h4>To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients.<h4>Methods and results</h4>In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator-initiated clinical trial, adults with type 2 diabetes and haemoglobin A1C (HbA1c) of 6.0-10.0% (42-86 mmol/mol) were randomized equally to ipragliflozin (50 mg daily) and non-sodium-glucose cotransporter-2 (SGLT2) inhibitor use of standard-care (control group) for type 2 diabetes and were followed-up to 24 months. The primary endpoint was the change in mean common carotid artery IMT (CCA-IMT) from baseline to 24 months. A total of 482 patients were equally allocated to the ipragliflozin (N = 241) and control (N = 241) groups, a2023-01-01T00:00:00Z2023 Feb2026-07-16T20:12:02.163Z2025-04-05T23:21:23.018ZS-EPMC98928693630829910.1093/ehjcvp/pvac059